Merck

Merck

Yahoo Finance • 11 hours ago

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular edema (DME) Remigromig is the first biologic with a novel mechanism of a... Full story

Yahoo Finance • 18 hours ago

Hospital group files lawsuit to stop 340B rebate pilot again

[An overturned pill bottle spills cash and medicinal capsules] Enrique Yocoyani Aguilar Licona/iStock via Getty Images The American Hospital Association has once again filed a lawsuit to halt a new pilot that tests a revised rebate model... Full story

Yahoo Finance • yesterday

Merck (MRK) Stock Trades Below Fair Value Despite Its 117% Run

Merck has been one of the stronger performers in big pharma over the past few years, and with the stock recently around US$145.60, the real issue for investors is whether that climb is still grounded in the cash the business can generate.... Full story

Yahoo Finance • 2 days ago

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Moderna stock jumps on planned national cancer vaccine effort

Moderna (MRNA) stock popped 9% on Friday after the New York Times reported new details about an effort to accelerate cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary. Other pharmaceutical... Full story

Yahoo Finance • 3 days ago

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

Moderna MRNA shares are set to join the Nasdaq-100 Index on Oct. 9, marking another milestone for the biotech after its sharp gains this year. The company will replace Warner Bros. Discovery in the index before the opening bell on Friday.... Full story

Yahoo Finance • 3 days ago

Pheochromocytoma and Paraganglioma (PCPG) Market to Reach US$670 Million by 2036 at 7.3% CAGR, Driven by Targeted and Radioligand Therapies

Company Logo Up from about US$300 million in 2025 across the US, EU4, UK and Japan, as Merck's WELIREG, the first oral targeted PCPG therapy, faces pipeline rivals from Novartis, Jazz and Perspective. Dublin, Oct. 08, 2026 (GLOBE NEWSWIR... Full story

Yahoo Finance • 3 days ago

Chronic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast - 2036 Report Reveals Why a Limited Pipeline Leaves the 7MM Market Without a Curative Leader

Company Logo 135-Page Report Tracks Bayer and Merck's ADEMPAS (Riociguat) as the Leading Therapy as Combination Regimens and Balloon Pulmonary Angioplasty Reshape CTEPH Treatment Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "Chronic Pulmona... Full story

Yahoo Finance • 3 days ago

Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?

Halozyme's argenx expansion puts ENHANZE back in focus Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock's pa... Full story

Yahoo Finance • 3 days ago

Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?

In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda in eight European countries following a patent dispute. This setback affe... Full story

Yahoo Finance • 4 days ago

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 days ago

Halozyme stock rises after winning injunction against Merck

Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets. Before you buy NVIDIA: our AI model's stock... Full story

Yahoo Finance • 4 days ago

15 dividend stocks beating the S&P 500 as markets sit near record highs

[Banknotes with the word DIVIDEND on a blue background. Business concept.] Mohd Azrin Wall Street remains close to record territory, even as a steady rise in Treasury yields gives some investors reason for caution. The S&P 500 (SP500 [ht... Full story

Yahoo Finance • 4 days ago

Tempus Announces Multi-Year Collaboration with Moderna and Merck

Collaboration to Support Potential Commercialization of Intismeran Autogene CHICAGO, October 07, 2026--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization... Full story

Yahoo Finance • 5 days ago

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses. Continue Reading... Full story

Yahoo Finance • 5 days ago

2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges

2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things a... Full story

Yahoo Finance • 6 days ago

Stock Market Today: Dow Up As Microsoft, SpaceX Pop; Brazil Play, Chip Leader Offer Entries (Live Coverage)

The Dow Jones index rises Monday. Brazil stocks soar on election results. Microsoft and SpaceX shine on the stock market today. Continue Reading... Full story

Yahoo Finance • 6 days ago

Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says. Continue Reading... Full story

Yahoo Finance • 6 days ago

Stock Market Today: Dow Dips, Brazil Stocks Soar On Bolsonaro Surprise; Microsoft, SpaceX Pop (Live Coverage)

The Dow Jones index falls Monday. Brazil stocks soar on Brazil election results. Microsoft and SpaceX shine on the stock market today. Continue Reading... Full story